Form 4: Ultragenyx Director Matthew K. Fust Sells Shares in Multiple Transactions

Director Matthew K. Fust of Ultragenyx Pharmaceutical Inc. reports selling shares of common stock in a series of transactions on March 7, 2024.

Summary

• On March 7, 2024, Matthew K. Fust, a director at Ultragenyx Pharmaceutical Inc., sold shares of the company's common stock.
• The sales were executed in multiple transactions at varying prices.
• A total of 2,550 shares were sold at a weighted average price of $50.89.
• An additional 2,145 shares were sold at a weighted average price of $50.85.
• Finally, 7,500 shares were sold at a weighted average price of $50.88.
• Following these transactions, Mr. Fust directly owns 14,860 shares of Ultragenyx common stock.

Sentiment

Score: 5

Explanation: This is a neutral report of stock sales by a company director. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, such as directors, who trade in their company's stock. It provides transparency to the market regarding insider transactions.

Stakeholder Impact

• The stock sale by a director could be perceived in various ways by stakeholders.
• Some might see it as a lack of confidence in the company's future, while others might view it as a personal financial decision.

Key Dates